Drug Trial Radar · NCT03621670
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,196
Actual
Start
Jul 27, 2018
Primary completion
Dec 27, 2024
Study completion Dec 27, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 weeks, up to 12 weeks
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccinesv(RIV).
Conditions
- Infections, Meningococcal
Interventions
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)Biological
Bexsero was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.
Prevnar13Biological
Prevnar13 (PCV13) was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.
PediarixBiological
Pediarix (DTPa-HBV-IPV) was administered intramuscularly on Day 1, Day 61, and Day 121.
HiberixBiological
Hiberix (Hib) was administered intramuscularly on Day 1, Day 61, and Day 121.
RotarixBiological
Rotarix (HRV) was administered intramuscularly on Day 1 and Day 61.
M-M-R IIBiological
M-M-R II (MMR) was administered intramuscularly on Day 301.
VarivaxBiological
Varivax (VV) was administered intramuscularly on Day 301.
Placebo (saline water)Biological
Placebo was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.
Prevnar 20Biological
Prevnar 20 (PCV13) was administered intramuscularly as a booster dose on Day 301 group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1Time frame: Day 1 to Day 7
- Number of Participants Reporting Any Solicited Systemic Events After the First Vaccination Administered at Day 1Time frame: Day 1 to Day 7
- Number of Participants Reporting Any Solicited Administration Site Events After the Second Vaccination Administered at Day 61Time frame: Day 61 to Day 67
- Number of Participants Reporting Any Solicited Systemic Events After the Second Vaccination Administered at Day 61Time frame: Day 61 to Day 67
- Number of Participants Reporting Any Solicited Administration Site Events After the Third Vaccination Administered at Day 121Time frame: Day 121 to Day 127
- Number of Participants Reporting Any Solicited Systemic Events After the Third Vaccination Administered at Day 121Time frame: Day 121 to Day 127
- Number of Participants Reporting Any Solicited Administration Site Events After the Fourth Vaccination Administered at Day 301Time frame: Day 301 to Day 307
- Number of Participants Reporting Any Solicited Systemic Events After the Fourth Vaccination Administered at Day 301Time frame: Day 301 to Day 307
- Number of Participants With Any Solicited Systemic AEs During the 30 Days After the Fourth Vaccination at Day 301Time frame: Day 301 to Day 330
- Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1Time frame: Day 1 to Day 30
- Number of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61Time frame: Day 61 to Day 90
- Number of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121Time frame: Day 121 to Day 150
- Number of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301Time frame: Day 301 to Day 330
- Number of Participants Reporting Any SAEs, AEs Leading to Withdrawal, AESIs and MAAEsTime frame: Day 1 up to study end (Day 481 for participants who have not reached 6-month follow-up at the time of Protocol Amendment 7; Day 661 for all others)
- Percentage of Participants With Human Serum Bactericidal Assay (hSBA) Antibody Titers >= Lower Limit of Quantitation (LLOQ) for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4) and M13520 (NHBA)Time frame: At Day 151 (1 month after the third vaccination)
- Percentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response)Time frame: At Day 151 (1 month after the third vaccination)
- Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA) and >= 16 for Strain 96217Time frame: At Day 331 (1 month after the fourth vaccination)
- Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains)Time frame: At Day 331 (1 month after the fourth vaccination)
- Adjusted Geometric Mean Concentrations (GMCs) of Immunoglobubin (IgG) Antibodies Against 13 PCV13 Antigens at 1 Month After Third VaccinationTime frame: At Day 151 (1 month after the third vaccination)
Locations
57 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Fayetteville, Arkansas
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
Roseville, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
West Covina, California
GSK Investigational Site
Lake Mary, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Nampa, Idaho
GSK Investigational Site
Nampa, Idaho
GSK Investigational Site
Newton, Kansas
GSK Investigational Site
Topeka, Kansas
GSK Investigational Site
Bardstown, Kentucky
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Fall River, Massachusetts
GSK Investigational Site
Bingham Farms, Michigan
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
Lincoln, Nebraska
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Liverpool, New York
GSK Investigational Site
Syracuse, New York
GSK Investigational Site
Boone, North Carolina
GSK Investigational Site
Raleigh, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Dayton, Ohio
GSK Investigational Site
Dayton, Ohio
GSK Investigational Site
Fairfield, Ohio
GSK Investigational Site
South Euclid, Ohio
GSK Investigational Site
Hermitage, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Sioux Falls, South Dakota
GSK Investigational Site
Clarksville, Tennessee
GSK Investigational Site
Kingsport, Tennessee
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.